Business context and reporting period
Filing identity: The request identifies Oruka Therapeutics, Inc., but the supplied Form 10-Q is for ARCA biopharma, Inc. for the quarter ended September 30, 2023. The summary below reflects the supplied filing, not Oruka.
ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidate, Gencaro, is being developed for atrial fibrillation in certain heart-failure patients; rNAPc2 (AB201) was studied as a potential COVID-19 treatment. The company continues a strategic-options review, with no defined timeline or assurance of a transaction.
Financial performance and position
Amounts are in U.S. dollars; financial statement amounts are in thousands unless stated otherwise.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| General and administrative expense | $1,615 | $1,528 | $4,740 | $4,360 |
| Research and development expense | $322 | $1,024 | $966 | $4,688 |
| Net loss | $(1,424) | $(2,333) | $(4,250) | $(8,752) |
| Basic and diluted loss per share | $(0.10) | $(0.16) | $(0.29) | $(0.61) |
| Net cash used in operating activities | Not presented quarterly | $(3,958) | $(9,418) |
Interest and other income was $513,000 in Q3 2023 and $1.456 million for the first nine months, compared with $222,000 and $301,000, respectively, in 2022; management attributed the increase to higher interest rates. Operating margins are not meaningful because ARCA reported no revenue.
At September 30, 2023, cash and cash equivalents were $38.487 million, down from $42.445 million at December 31, 2022. Total current assets were $38.892 million and current liabilities were $992,000. Total liabilities were $1.216 million, including operating lease liabilities; the filing reports no borrowings. Stockholders’ equity was $37.968 million.
Changes versus prior periods
- Q3 net loss narrowed by about 39% year over year; nine-month net loss narrowed by about 51%.
- Nine-month R&D expense fell by $3.722 million, primarily because rNAPc2 Phase 2b trial close-out and manufacturing costs were incurred mainly in 2022, and because of lower personnel costs following a 2022 workforce reduction.
- Nine-month G&A expense rose by $380,000, reflecting higher professional fees, partly offset by lower personnel and termination costs.
- Operating cash use improved by $5.460 million year over year. Cash declined by $3.958 million during the first nine months of 2023; there were no investing or financing cash flows in that period.
Outlook, risks and unusual items
- Management expects existing cash to fund operations through the end of fiscal 2024, but cautions that assumptions may prove wrong and that the strategic review could affect the projection. Initiating a Gencaro Phase 3 trial, including PRECISION-AF, would require additional financing.
- ARCA may need equity, debt, partnerships or a strategic transaction to continue development and operations. Financing may be unavailable or dilutive; without sufficient funding or a transaction, the company may delay, reduce or discontinue activities.
- The strategic review may not result in a transaction, and any transaction may not increase stockholder value. The company also cites Nasdaq listing, clinical, regulatory, enrollment, manufacturing, third-party collaboration, intellectual-property and market-access risks.
- Gencaro has an FDA Special Protocol Assessment for a planned Phase 3 trial, but the filing emphasizes that this does not guarantee trial success or FDA approval. The rNAPc2 Phase 2b trial did not achieve statistical significance on its primary D-dimer endpoint; secondary results numerically favored rNAPc2 but were non-significant.
- ARCA recorded $159,000 of severance expense in the first nine months of 2023 related to a former executive’s departure. It also reported $432,000 of unpaid research-grant expense related to the CEO’s academic laboratory at September 30, 2023.
- The filing reports effective disclosure controls and no material change in internal control over financial reporting during the quarter. It lists no legal proceedings.
Most important facts to verify
- Confirm the issuer: the supplied filing is ARCA biopharma, Inc., not Oruka Therapeutics, Inc.
- Check whether the strategic review has produced any transaction, partnership or development decision since September 30, 2023.
- Verify cash runway assumptions and the timing, cost and funding plan for any Gencaro Phase 3 trial or further rNAPc2 development.
- Reconcile the filing’s differing 2022 restructuring-charge figures: the notes report approximately $755,000, while MD&A refers to approximately $790,000.
- Review Nasdaq listing status, potential dilution from future financing, and the status of the at-the-market facility; the filing says no shares were sold under it in 2023 or 2022 and estimates approximately $7.1 million of availability as of October 17, 2023, subject to a public-float limit.